Mesoblast (ASX:MSB) reported Friday fiscal first-half loss of $0.0311 per share, compared with $0.042 a year earlier.
Revenue for the six months ended Dec. 31, 2025, was $51.3 million, compared with $3.2 million a year earlier. Analysts surveyed by FactSet expected $53.1 million.
The company said it expects fiscal 2026 net revenue of Ryoncil, the company's mesenchymal stromal cell therapy, to range between $110 million and $120 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments